Chronic Obstructive Pulmonary Disease (COPD) Market Research Report: Information by COPD Type (Emphysema and Chronic Bronchitis), Treatment Type (Drugs, Surgery and Oxygen Therapy), End User (Hospitals & Clinics, Home Care Settings and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027
ID: MRFR/Pharma/1081-HCR | February 2021 | Region: Global | 90 pages
Chronic Obstructive Pulmonary Disease (COPD) Market
Chronic Obstructive Pulmonary Disease (COPD) Market is expected to register a CAGR of 4.5% to touch USD 25.7 Billion from 2020 TO 2027.
$25.7 Billion
Market Size
4.5%
CAGR
North America
Dominating Region
2020-2027
Forecast Period
Segmentation
Key Players
- bbott (USA)
- AstraZeneca (UK)
- Dr. Reddy’s Laboratories Ltd (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GSK (UK)
- Merck (USA)
- Novartis AG (Switzerland)
- Pfizer Inc (USA)
Drivers
- Rise in incidence and the prevailing
- Increase in demand for the drugs
Chronic obstructive pulmonary disease is a chronic disorder of the lungs that inhibits the airflow to the lungs. Globally it has been noticed that the factor lying behind this disorder is the rise in the number of cases within the public. Revolution in the lifestyle of the people like to enhance in their habits of smoking and drinking and besides it, many other genetic diseases have increased the chronic obstructive pulmonary disease cases. Spending money on healthcare is enhancing the facilities in developing countries for COPD. Arranging rallies for making them aware of chronic pulmonary disease across developed and underdeveloped countries have increased the growth of the chronic obstructive pulmonary disease market. Research has been still carried out to solve the complexity of the market situations faced in this sector. The key players so present follows the chronic obstructive pulmonary disease market trend giving the right solutions to the client’s problems by using the right methods of their research.
Chronic Obstructive Pulmonary Disease (COPD) Market is expected to register a CAGR of 4.5% to touch USD 25.7 Billion from 2020 TO 2027.
COVID 19 ANALYSIS
The breakdown of COVID has become a risk factor for chronic obstructive pulmonary disease. Initially, it was in less count and gradually it increased. Due to this situation, the supply of respiratory ailment devices to the hospitals was hindered in most of the places. Patients suffering from both COVID and COPD were undergoing with worst ailment conditions. COVID situation brought no significant difference in the condition of the chronic obstructive pulmonary disease patients. The public during this situation was advised to stay indoors and will only move out if they had to concern a doctor. They were advised to move with proper precautions liking wearing masks, gloves and hair caps, etc.
It has affected the COPD market and its prolonged effect will have a bad impact on the market during the chronic obstructive pulmonary disease forecast period. From chronic obstructive pulmonary disease market analysis, you can notice the change in consumer behavior and their demand thus affected the supply chain. Some of the policies and certain regulations regarding the COVID are put forward by the government. The government has imposed strict rules and regulations against COVID.
Regional Market Summary
Global Chronic Obstructive Pulmonary Disease (COPD) Market Share (%), by Region, 2018 
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports
MARKET DYNAMICS
- Drivers- donating of larger funds from government and pharmaceutical companies for manufacture and launching of new drugs and R and D drives up the chronic obstructive pulmonary disease market value. The rise in incidence and the prevailing condition of asthma and COPD and the rise in the geriatric population are the major driving factors of the COPD market.
- Opportunities- government making allowance for the drugs and biosimilars provides great opportunities for the chronic obstructive pulmonary disease global market value. Advancement of the hospital infrastructure, lifestyle changes, and disposable income are the factors that make the CPOD market to be at the top.
- Challenges- launching a new product is the major challenge for the market. Depending on its advantage and disadvantage the positive and its negative effects poses severe challenges on the chronic obstructive pulmonary disease global market. Demand for homecare therapeutic instruments and devices becomes a challenging factor for the CPOD market.
- Cumulative growth - Chronic obstructive disease has been prevailing in the world for since long. Development of new products and launching them as per new technology is steering up the chronic obstructive pulmonary disease market growth. The increase in demand for the drugs for the suffering persons targetting their treatment boosts the growth. Researchers are still now carrying research for evaluation of their efficacy which will be safer for the patients.
- Restraints- spending a large amount on COPD treatment and having fewer ideas and knowledge about the disease are the major restraints affecting the chronic obstructive pulmonary disease global market growth Patent expiry is the anothe4r factor affecting the growth and chronic obstructive pulmonary disease industry value. Patients responding negatively to combination therapy act as a restraint to chronic obstructive pulmonary disease industry growth. The demand for generic drugs has affected the growth and manufacture of drugs. Strict government regulations for the manufacture and launching of new products act as major restraints for the market.
VALUE CHAIN ANALYSIS
The value chain analysis offers the idea of revenue generation into the overall market space. It provides insights about how vendors are practicing and carrying out in terms of revenue generation and customer base case. Having ideas about the market share and the competitiveness and the chronic obstructive pulmonary disease market size. The COPD market also gives information about the characteristics of the chronic obstructive pulmonary market value.
SEGMENT OVERVIEW
- By type- as per the type, the chronic obstructive pulmonary disease is bifurcated into chronic bronchitis and emphysema. Emphysema leads to the wear and tear of the fragile elastic walls and fibers of alveoli. During exhalation, the airways collapse impairing the airflow while in the former case causing inflammation of bronchial tubes leading to the production of more mucus. The chronicle market is divided into hospitals, clinics, home care settings, and many others. Hospitals and clinics are dominant and cover a large part of the chronic obstructive pulmonary disease market share.
- By technology- the advancement of technology increases the opportunities for advanced treatment of COPD. Advanced technology encourages the development of drugs, thus increasing the chronic obstructive pulmonary diseases market size. Technology has been applied in every field like in the medical sector which has improved the mapping of COPD epidemiology. It has cleared our understanding of the disease and has imposed the development of therapies in the COPD market. The drugs and the diagnosis so carried out show promising consequences that are efficient enough. Technology has provided end-to-end solutions for every disease.
REGIONAL ANALYSIS
North America is expected to be the first dominant region covering a large area of market share. The Asia Pacific is marked to be the next dominant market covering the largest portion due to its large population ratio. Asia Pacific region includes the regions of Indonesia, Philippines, China, some portions of Thailand, and India. Developed by revenue COPD in North America covers a chronic obstructive pulmonary disease market share followed by Europe. All the above regions form a constant array of chains carrying out new methods and formulas for the discovery of the drug. The prevalence of the drug market in Japan has helped the region to flourish in a better way. These regions have strengthened their positions in the chronic obstructive pulmonary disease industry.
COMPETITIVE LANDSCAPE
Some competitors of the COPD in the chronic obstructive pulmonary disease market include Abbott Laboratories in the US, Circassia Pharmaceuticals in the UK, Almirall in Spain, Japan’s Astellas Pharma, AstraZeneca of United Kingdom, United Kingdom’s GlaxoSmithKline, Novartis of Switzerland, Pfizer, Teva Pharmaceutical Industries Ltd, Boeringhar Ingelheim of Germany, etc. these competitors involve in merging and making partnership with other countries. They carry out various expansion strategies and adopting the new chronic obstructive pulmonary disease market outlook for various marketing penetration. By following the chronic obstructive pulmonary disease industry outlook they are launching new products and are carrying out acquisitions which helps in substantial chronic obstructive pulmonary disease industry growth. Before collaborating they take license for consolidation of their product portfolio.
REPORT OVERVIEW
Globally the chronic obstructive pulmonary disease market is providing a good evaluation about the chronic obstructive pulmonary disease market outlook. It also provides a good analysis of the drivers, its segment overview, restraints, and the challenges that are being prolonged in the chronic marketing sector. This market analysis gives a holistic insight into the market globally. It also entitles the financial statement of the competitors with product benchmarking and SWOT analysis. It emphasizes the developmental strategies put forward by the key players and their rank order in the market. The segmentation so done in the marketing sector shows the expansion of chronic obstructive pulmonary disease market size and chronic obstructive disease market outlook. It also assesses and gives a clear picture of the qualitative and quantitative techniques which assists the clients which increases their skills to make the proper decision regarding the business.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: 25.7 Billion |
| CAGR | 4.7% (2020-2027) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | COPD Type, Treatment Type and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) |
| Key Market Opportunities | People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The valuation of the global chronic obstructive pulmonary disease (COPD) market had reached USD 25.7 Billion By 2027
The main types of chronic obstructive pulmonary disease (COPD) are emphysema and chronic bronchitis.
The treatments included in the Chronic Obstructive Pulmonary Disease Treatment (COPD) Market are Drugs, Surgery and Oxygen Therapy.
Technological advancements and new product launches and increasing demand for home care therapeutic devices are the major tailwinds pushing the growth of the global chronic obstructive pulmonary disease (COPD) market.
North America holds the largest share in the chronic obstructive pulmonary disease (COPD) market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca (UK), Abbott (USA), Dr. Reddy’s Laboratories Ltd (India), GSK (UK), F. Hoffmann-La Roche Ltd (Switzerland), Merck (USA), Pfizer Inc. (USA), and Novartis AG (Switzerland), are some of the major players operating in the chronic obstructive pulmonary disease (COPD) market.
The chronic obstructive pulmonary disease (COPD) market is projected to grow at approximately 4.7% CAGR during the assessment period (2020-2027)
